Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial assessing addition of M3814 (peposertib) to the standard mitoxantrone, etoposide, and cytarabine regimen for relapsed or refractory acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• M3814
• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING